Axsome Therapeutics, Inc. (AXSM)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Axsome Therapeutics, Inc. (AXSM)
Company Performance

Current Price

as of Dec 03, 2024

$100.49

P/E Ratio

N/A

Market Cap

$4.87B

Description

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerAXSM
  • Price$100.49+1.42%

Trading Information

  • Market cap$4.87B
  • Float81.56%
  • Average Daily Volume (1m)622,581
  • Average Daily Volume (3m)476,778
  • EPS-$6.54

Company

  • Revenue$338.46M
  • Rev growth (1yr)81.27%
  • Net income-$64.60M
  • Gross margin89.98%
  • EBITDA margin-42.16%
  • EBITDA-$44.17M
  • EV$4.19B
  • EV/Revenue12.38
  • P/EN/A
  • P/S14.29
  • P/B52.39
Documents
SEC Filings
8-K (2024-11-26)
8-K (2024-11-12)
8-K (2024-10-01)
8-K (2024-09-04)
8-K (2024-08-21)
8-K (2024-08-05)
8-K (2024-06-11)
8-K (2024-06-05)
8-K (2024-05-06)
8-K (2024-04-01)
8-K (2024-03-25)
8-K (2024-03-19)
8-K (2024-02-20)
8-K (2024-01-08)
8-K (2024-01-04)
8-K (2023-12-07)
8-K (2023-11-06)
8-K (2023-10-11)
8-K (2023-08-15)
8-K (2023-08-07)
8-K (2023-08-04)
8-K (2023-07-07)
8-K (2023-06-30)
8-K (2023-06-29)
8-K (2023-06-26)
8-K (2023-06-13)
8-K (2023-06-08)
8-K (2023-05-08)
8-K (2023-03-13)
8-K (2023-03-10)
8-K (2023-02-27)
8-K (2023-02-22)
8-K (2023-02-13)
8-K (2023-01-09)
10-Q (2024-11-12)
10-Q (2024-08-05)
10-Q (2024-05-06)
10-Q (2023-11-06)
10-Q (2023-08-07)
10-Q (2023-05-09)
10-K (2024-02-23)
10-K (2023-02-28)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Axsome Therapeutics Q3 ($ 65.14, 0.00) (2023-11-06T14:21:43Z)
Axsome Therapeutics reports Q3 EPS ($1.32) vs FactSet ($1.20) [11 est, ($1.33)-(0.93)] ($65.14, 0.00) (2023-11-06T12:03:44Z)
Axsome Therapeutics presents results of the ACCORD trial of AXS-05 in Alzheimer's disease agitation at CTAD ($62.01, 0.00) (2023-10-24T11:08:01Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-06)
Earnings Report (2023-08-07)